Global Growth Hormone Deficiency Market Size To Exceed USD 9.80 Billion By 2035 | CAGR of 5.1%

Global Growth Hormone Deficiency Market Size To Exceed USD 9.80 Billion By 2035

According to a Research Report Published By Spherical Insights & Consulting, The Global Growth Hormone Deficiency Market Size is Expected To Grow From USD 5.67 Billion in 2024 to USD 9.80 Billion By 2035, at a CAGR of 5.1% During The Forecast Period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the" Global Growth Hormone Deficiency Market Size, Share, and COVID-19 Impact Analysis, By Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and Others), By Applications (Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome, Adult Growth Hormone Deficiency, Prader-Willi Syndrome, and Others), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Clinics, and E-Commerce Websites), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/growth-hormone-deficiency-market          

The growth hormone deficiency (GHD) market involves the diagnosis, treatment, and management of GHD, a rare endocrine disorder in which the pituitary gland produces insufficient growth hormone, affecting growth in children and metabolism in adults. The market primarily focuses on recombinant human growth hormone (rhGH), which promotes growth, enhances muscle mass, and regulates metabolic functions. The increasing prevalence of hormonal disorders, combined with growing awareness among patients and physicians, is expected to drive market growth. Advances in biotechnology are enabling the development of safer and more effective recombinant and long-acting formulations. Additionally, innovations in drug delivery, such as needle-free systems and once-weekly injections, enhance patient adherence and convenience, further boosting adoption. Ongoing clinical trials are exploring novel applications of GH therapy in ageing, Turner syndrome, chronic kidney disease, and other emerging indications, expanding potential market opportunities. High treatment costs, limited access in developing regions, and strict regulatory approvals are restraining market growth.

The norditropin segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the brand, the growth hormone deficiency market is divided into norditropin, genotropin, humatrope, saizen, omnitrope and others. Among these, the norditropin segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Norditropin’s effectiveness in treating growth hormone deficiency, backed by extensive clinical studies, strengthens its competitive advantage. Its premixed, prefilled pen system provides convenient administration, eliminating manual preparation, and making it a preferred option for patients.

The pediatric growth hormone deficiency segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the applications, the growth hormone deficiency market is divided into pediatric growth hormone deficiency, idiopathic short stature, small for gestational age, turner syndrome, adult growth hormone deficiency, prader-willi syndrome, and others. Among these, the pediatric growth hormone deficiency segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Pediatric growth hormone deficiency, marked by low growth hormone secretion in children, holds a significant market share due to rising GHD prevalence, increased drug availability by key players, growing awareness, and active development of new growth hormone therapies.

The hospital pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channels, the growth hormone deficiency market is divided into hospital pharmacies, retail pharmacies, clinics, and e-commerce websites. Among these, the hospital pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Many hospitals require patients to purchase prescribed medications on-site. Additionally, substantial government investments in advanced healthcare facilities worldwide support the distribution of growth hormone therapies through hospital pharmacy channels.

North America is expected to hold the majority share of the global growth hormone deficiency market during the forecast period.

North America is expected to hold the majority share of the global growth hormone deficiency market during the forecast period. Market growth is driven by advanced healthcare infrastructure and easy access to growth hormone therapies. Rising awareness of GHD, early diagnosis, robust insurance coverage, ongoing research, active key players, and supportive government initiatives for rare disease management further contribute to sustained expansion in the region.

Asia Pacific is anticipated to grow at the fastest pace in the global growth hormone deficiency market during the forecast period. Market growth is fueled by rising awareness of pediatric and adult GHD, increased healthcare spending, expanding infrastructure, and better access to advanced therapies. Government rare disease initiatives, improved diagnostics, large patient populations, and multinational companies’ regional expansion further drive adoption.

Major vendors in the global growth hormone deficiency market are Pfizer Inc., Novo Nordisk A/S, Ipsen S.A., Merck KGaA, Eli Lilly and Company, Ferring Pharmaceuticals, Novartis AG, AnkeBio Co., Ltd, F. Hoffmann La Roche Ltd, EMD Serono Inc., Ascendis Pharma A/S, Teva Pharmaceutical Industries Ltd., Anhui Anke Biotechnology Group Co., Ltd, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)
•  

Key Market Development 

• In September 2023, Ascendis Pharma introduced SKYTROFA (lonapegsomatropin) in Germany. EU-approved, it delivers once-weekly therapy for children and adolescents (3–18 years) with growth failure due to GHD, providing an effective and convenient treatment option.

• In December 2021, Pfizer announced that the EMA’s CHMP issued a positive opinion recommending somatrogon, a once-weekly long-acting recombinant human growth hormone, for marketing authorisation. It is intended to treat children and adolescents aged three and older with growth disturbances caused by insufficient endogenous growth hormone secretion.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the growth hormone deficiency market based on the below-mentioned segments:

Global Growth Hormone Deficiency Market, By Brand

• Norditropin
• Genotropin
• Humatrope
• Saizen
• Omnitrope
• Others

Global Growth Hormone Deficiency Market, By Applications

• Pediatric Growth Hormone Deficiency
• Idiopathic Short Stature
• Small for Gestational Age
• Turner Syndrome
• Adult Growth Hormone Deficiency
• Prader-Willi Syndrome
• Others

Global Growth Hormone Deficiency Market, By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Clinics
• E-Commerce Websites

 Global Growth Hormone Deficiency Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter